title: Molecular classification of patients with malignant melanoma for new therapeutic strategies.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palmieri
authors.forename: Milena
authors.initials: M
authors.lastname: Casula
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: Francesco
authors.initials: F
authors.lastname: Tanda
authors.forename: Antonio
authors.initials: A
authors.lastname: Cossu
mesh_terms: D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000502:physiology; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000235:genetics; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000188:drug therapy*; D013873:Thionucleotides / Q000008:administration & dosage*
chemical_list: D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D013873:Thionucleotides; D003606:Dacarbazine; C408162:oblimersen; D048049:Extracellular Signal-Regulated MAP Kinases